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Abstract  
Reduced levels of high density lipoprotein cholesterol (HDL) are associated with a 
substantially increased risk of coronary disease and cardiovascular events.  Furthermore, 
numerous studies have suggested that HDL may exert several potentially important anti-
atherosclerotic and endothelial-protective effects.  In particular, the promotion of reverse 
cholesterol transport, i.e. cholesterol efflux from lipid-loaded macrophages in atherosclerotic 
lesions and the subsequent cholesterol transport back to the liver, has been proposed as an 
anti-atherogenic effect of HDL that may promote regression of atherosclerotic lesions.  
Moreover, endothelial dysfunction is thought to play a critical role in development and 
progression of atherosclerosis and several recent studies have suggested that HDL exerts 
direct endothelial-protective effects, such as stimulation of endothelial production of the anti-
atherogenic molecule nitric oxide, anti-oxidant, anti-inflammatory and anti-thrombotic 
effects.  Furthermore, it has been observed that HDL may stimulate endothelial repair 
processes, involving mobilisation and promotion of endothelial repair capacity of endothelial 
progenitor cells.  The relative significance of these different potential anti-atherosclerotic 
effects of HDL remains still unclear at present.  Importantly, at the same time it has been 
recognized that the vascular effects of HDL may be variable, i.e. the capacity of HDL to 
stimulate macrophage cholesterol efflux and endothelial-protective effects may be altered in 
patients with inflammatory or cardiovascular disease.  The further characterisation of 
underlying mechanisms and the identification of the clinical relevance of this “HDL 
dysfunction” are currently an active field of research. HDL-targeted treatment strategies are 
at present intensely evaluated and may lead to increased HDL plasma levels and/or HDL-
stimulated anti-atherosclerotic effects.  The cardiovascular protection provided by such 
approaches may likely depend on HDL function or quality, i.e. the anti-atherosclerotic and 
endothelial-protective properties of the on-treatment HDL.  Currently, several HDL-raising 
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treatment strategies are examined in clinical trials, i.e. extended-release niacin, the CETP 
inhibitors dalcetrapib and anacetrapib, reconstituted forms of HDL (i.e. CSL-111) or apoA-I 
mimetics, and some of these are already in large clinical outcome studies on top of statin 
therapy to determine their efficacy and safety for cardiovascular prevention. 
 
Keywords:   High density lipoprotein; Endothelium; Nitric oxide; Inflammation; Endothelial 
progenitor cells; Atherosclerosis; Coronary artery disease 
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1. INTRODUCTION 
Reduced plasma levels of high density lipoprotein (HDL) cholesterol are associated with an 
increased risk of coronary disease [1-5], and numerous studies have suggested that HDL may 
exert anti-atherogenic effects, such as promoting cholesterol-efflux from lipid-loaded 
macrophages, anti-inflammatory and endothelial-protective effects. Accordingly, 
interventions to increase HDL-levels and/or HDL-function are currently intensely evaluated 
as a potential novel therapeutic strategy to reduce cardiovascular risk.    
In the present review, we will therefore discuss potential mechanisms whereby HDL may 
exert atheroprotective effects and address the heterogeneity of HDL particles and function in 
inflammatory and cardiovascular disease.  Importantly, recent data suggest that the vascular 
effects of HDL can be markedly altered in patients with diabetes or inflammatory diseases.  
Finally, we will provide an overview of potential therapeutic strategies increasing HDL 
plasma concentrations and/or function. 
 
1.1 HDL cholesterol plasma levels, genetic variants leading to altered HDL cholesterol 
plasma levels and coronary heart disease risk 
Numerous studies have indicated that lower plasma levels of HDL cholesterol are associated 
with an increased risk of coronary disease and coronary disease-related cardiovascular events 
[1-4]. Furthermore, it has been observed, that this does also apply to patients with coronary 
disease and very low levels of low density lipoprotein (LDL) cholesterol on statin therapy, as 
suggested by a post-hoc analysis of the Treating to New Targets trial [5]. More recently, a 
large analysis involving more than 300,000 people without initial vascular disease, mostly 
from Europe and North America, demonstrated that reduced HDL cholesterol levels were 
strongly associated with an increased coronary heart disease risk, whereas no such association 
was observed for triglyceride levels after adjustment for other cardiovascular risk factors [6]. 
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Several recent studies have examined the association of genetic variations leading to altered 
HDL plasma levels, i.e. due to ATP binding cassette transporter A1 (ABCA1) mutations or 
genetic variants of the cholesteryl ester transfer protein (CETP), with coronary disease risk 
[7, 8]. In a study from Denmark, reduced HDL cholesterol levels were associated with an 
increased risk of ischemic heart disease, however, lower plasma levels of HDL cholesterol 
due to heterozygosity for four rare loss-of-function mutations in the ABCA1 gene were not 
associated with an increased risk of ischemic heart disease in this study [7]. The number of 
subjects being heterozygous for the rare ABCA1 mutations in this analysis was, however, 
rather low, i.e. 109 subjects, that may limit conclusions about clinical outcome in these 
subjects.  Furthermore, subjects with the rare ABCA1 mutations had also 25% lower LDL 
cholesterol levels, that may potentially offset a risk associated with the reduced HDL levels 
[9]. In a study examining three genotypes for CETP, that were associated with a moderate 
inhibition of CETP activity and, therefore, modestly higher HDL cholesterol levels, a weakly 
inverse association with a reduced coronary risk was observed [8]. 
 
2. POTENTIAL ANTI-ATHEROGENIC AND ENDOTHELIAL-
PROTECTIVE EFFECTS OF HDL 
In recent years, several functions of HDL have been identified, that may account for the 
ability of HDL to protect against atherosclerosis (Fig. 1) [10-12]. Besides promoting 
macrophage cholesterol efflux and reverse cholesterol transport, HDL has been shown more 
recently to exert direct vasoprotective effects, such as endothelial-protective, anti-
inflammatory and anti-thrombotic effects, that will be discussed in detail below. Although the 
basis of atheroprotection provided by HDL is complex and has yet to be fully clarified, recent 
evidence suggests that the vascular effects of HDL may be highly heterogenous and 
vasoprotective properties of HDL may be limited in certain patient populations [13, 14]. 
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2.1 HDL and reverse cholesterol transport from macrophages 
The term macrophage reverse cholesterol transport (RCT) is generally used to describe the 
process by which unesterified cholesterol is exported from macrophages in atherosclerotic 
lesions of the arterial wall and returned to the liver for excretion in the bile [15]. 
 
2.1.1 Macrophage cholesterol efflux  
The first step of macrophage RCT includes the hydrolysis of cytoplasmatic cholesterol esters 
to free cholesterol and the efflux of free cholesterol to extracellular lipid-poor apolipoprotein 
(apo) A-I or mature HDL.  Early on, efflux of cholesterol from macrophages was thought to 
be primarily mediated by passive diffusion [16].  Now it has become clear that macrophage 
cholesterol efflux is facilitated by active tranport systems, including the ABCA1, ATP 
binding cassette transporter G1 (ABCG1) and scavenger receptor class B type I (SR-BI) [15, 
17, 18]. 
Studies in macrophages from ABCA1 knockout or overexpressing mice have indicated that 
ABCA-1 primarily mediates cholesterol efflux to lipid poor apoA-I [19-21].  Of note, 
transplantation of bone marrow from ABCA1 knockout mice into hypercholesterolemic 
apoE- or LDL receptor-deficient mice resulted in an increase in atherosclerotic lesion 
progression, suggesting that cholesterol efflux via ABCA1 indeed plays an important role in 
preventing atherosclerotic vascular disease [22]. However, rates of cholesterol excretion into 
the bile were normal in ABCA1 knockout mice [23] indicating that the quantitative role of 
ABCA1 in contributing to macrophage cholesterol efflux and RCT in vivo remains to be 
further characterized. Moreover, these studies could not prove that the increased 
atherosclerosis in ABCA1 knockout mice was due to impaired macrophage cholesterol 
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efflux, but could also have other explanations, such as ABCA1-dependent export of oxidized 
phospholipids from vascular cells [15].  
In contrast to ABCA1, ABCG1 and SR-BI largely mediate cholesterol efflux from 
macrophages to mature HDL, which might be more efficient in mediating RCT in vivo than 
lipid poor apoA-I, also since mature HDL represents a much larger proportion of HDL and 
apoA-I found in plasma as compared to the limited amount of lipid-poor apoA-I [24]. 
However, studies characterizing the effect of ABCG1 and SR-BI on macrophage RCT and 
development of atherosclerosis in mice have yielded controversial results. Whereas ABCG1-
deficient mice displayed increased diet-induced lipid accumulation in macrophages [25] and 
one group reported accelerated early atherosclerotic lesion development in these mice [26], 
other groups found a decreased atherosclerotic plaque burden in atherosclerosis prone mice 
transplanted with ABCG1-deficient bone marrow [27, 28]. Potential explanations for these 
conflicting results might be a compensatory upregulation of ABCA1 and apoE, increased 
apoptosis of macrophages due to lipid accumulation and the stage of atherosclerotic lesion 
development [29]. Of note, a recent study quantitatively assessed the roles of ABCA1, 
ABCG1 and SR-BI in macrophage RCT in vivo [30]. By using primary macrophages lacking 
SR-BI the authors were able to demonstrate that SR-BI did not promote macrophage RCT in 
vivo after intraperitoneal injection in wild type mice [30]. In contrast to SR-BI, ABCA1 and 
ABCG1 contributed in an additive fashion to stimulation of macrophage RCT in vivo [30] 
and transplantation of bone marrow from ABCA1 / ABCG1-deficient mice accelerated 
atherosclerotic lesion formation in LDL receptor-deficient mice [31]. Consistent with these 
findings, Yvan-Charvet et al. [32] were able to demonstrate that SR-BI fails to stimulate net 
cholesterol efflux from HEK293 cells to plasma HDL and inhibits ABCG1-mediated 
cholesterol efflux, at least in part due to an increased uptake of HDL cholesteryl esters into 
HEK293 cells. These studies suggest that previous findings of accelerated atherosclerosis in 
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apoE- and LDL receptor-deficient mice transplanted with bone marrow from SR-BI deficient 
mice [33, 34] cannot be explained by decreased macrophage cholesterol efflux. 
 
2.2.2 Cholesterol esterification by lecithin-cholesterol acyltransferase (LCAT) 
Following efflux from macrophages, a proportion of HDL-associated free cholesterol in 
plasma is esterified to cholesteryl ester by lecithin-cholesterol acyltransferase (LCAT).  
Although LCAT activity allows the formation of a hydrophic core in HDL and thereby plays 
an important role in the formation of mature HDL particles, the relevance of LCAT for RCT 
remains controversial [35].  Recently, it has been suggested that LCAT activity is not 
required for the ability of human plasma to promote macrophage cholesterol efflux in vitro 
[36] and may have a minor role for macrophage RCT in vivo [37], consistent with the 
observation that HDL directly transfers a large amount of unesterified cholesterol to the liver 
for biliary cholesterol excretion [38, 39].  Moreover, a recent study suggested that carotid 
intima media thickness was not increased in a cohort (n=40) of individuals with loss-of-
function mutations in LCAT [40]. 
 
2.2.3 Cholesterol uptake to the liver 
The final step of RCT comprises the uptake of HDL-associated cholesterol to the liver. HDL 
cholesterol can be delivered directly to the liver by selective uptake of cholesteryl ester and 
unesterified cholesterol by hepatic SR-BI [15, 41]. Of note, overexpression of hepatic SR-BI 
increased macrophage RCT in mice, although plasma levels of HDL cholesterol were 
reduced [42], suggesting that hepatic SR-BI expression is inversely related to atherosclerosis 
development. Alternatively, in humans and in some other species HDL cholesterol can be 
transferred to apoB-containing lipoproteins in exchange for triglycerides via the cholesteryl 
ester transfer protein (CETP) and subsequently be cleared by LDL receptor-mediated uptake 
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of apoB-containing lipoproteins to the liver.  Indeed, in mice with CETP gene transfer (that 
normally lack CETP) there was evidence for an increased macrophage RCT [43].  However, 
HDL isolated from human subjects with homozygous CETP deficiency had an increased 
cholesterol efflux potential [44].   Therefore, the relevance and effect of modulation of CETP 
activity or levels for macrophage cholesterol efflux and RCT remains to be further 
determined.   
 
2.2 HDL and stimulation of endothelial NO-synthase dependent nitric oxide (NO) 
production  
In recent years, numerous experimental and clinical studies have suggested that endothelial 
production of nitric oxide (NO) plays a crucial role in the regulation of vascular tone and 
structure [45, 46]. Besides stimulation of endothelium-dependent vasodilation, endothelial 
NO has been shown to exert a variety of atheroprotective effects in the vasculature, such as 
anti-inflammatory, anti-thrombotic, anti-coagulant and pro-fibrinolytic effects [45]. 
Therefore, endothelial NO-synthase (eNOS) derived NO is considered as a critical 
determinant of vascular homeostasis and an important anti-atherogenic molecule. Endothelial 
dysfunction, likely a consequence of reduced endothelial NO bioavailability, is considered to 
play an important role in the development and progression of atherosclerosis [45]. 
The understanding of the vascular effects of HDL considerably changed with the important 
observation that HDL may directly stimulate eNOS-mediated NO production and induce 
endothelium-dependent, NO-mediated vasodilation [47]. Meanwhile, several experimental 
studies have consistently demonstrated the capacity of HDL to modify eNOS expression and 
activity and to stimulate endothelial production of NO in vitro and in vivo [14, 48-51].  
Moreover, in humans, administration of reconstituted HDL has been shown to correct 
impaired endothelium-dependent, NO-mediated vasorelaxation in subjects with isolated low 
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levels of HDL due to a ABCA1 mutation as well as in patients with hypercholesterolemia by 
restoring NO bioavilability [52, 53].  
Several different mechanisms have been proposed to account for the endothelial NO-
stimulating capacity of HDL (Fig. 2). Early studies have suggested that HDL acts by 
preventing the detrimental effects of oxidized LDL on endothelial NO-synthase [54].  A 
subsequent study by Yuhanna et al. [47] suggested that HDL can directly stimulate eNOS-
mediated NO production by binding to SR-BI on endothelial cells. 
Although the signaling events underlying stimulation of eNOS upon binding of HDL to SR-
BI are complex, recent studies have provided important insights into proximal mechanisms 
that are involved in HDL-induced signal transduction in endothelial cells (Fig. 2). Binding of 
HDL to SR-BI initially leads to tyrosine kinase Src-mediated activation of  phosphoinositide 
(PI) 3-kinase  and PI3-kinase in turn activates Akt and the MAP kinase/extracellular signal-
regulated kinase pathway [49]. Activation of endothelial Akt by HDL has been shown to 
stimulate phosphorylation of eNOS at serine residue 1177 [49, 51], that is known to be an 
important regulatory mechanism leading to eNOS activation [55]. In contrast, the mechanism 
whereby the MAP kinase/extracellular signal-regulated kinase pathway activates eNOS in 
endothelial cells stimulated with HDL remains to be further characterized [56]. 
However, in these studies isolated apoA-I, i.e. the major SR-BI ligand of HDL, failed to 
activate eNOS, suggesting that other HDL components besides apoA-I are likely to be 
important for the eNOS-stimulating capacity of HDL.  Interestingly, stimulation of eNOS-
mediated NO production is also induced by binding of HDL-associated lysophospholipids 
(i.e. sphingosylphosphorylcholine, sphingosine-1-phosphate, lysosulfatide) to the 
lysophospholipid receptor S1P3 (Fig. 2), that is expressed in endothelial cells and may 
partially mediate HDL- and lysophospholipid-induced vasodilation [51, 56]. Of note, the 
vasodilatory response to HDL was not completely inhibited in S1P3 deficient mice.  This may 
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suggest an interaction between SR-BI and S1P3 to induce HDL signalling in endothelial cells. 
An interaction of HDL with SR-BI could provide the necessary spatial proximity for 
lysophospholipids to effectively stimulate S1P3 [51].  However, further studies are needed to 
characterize the most proximal signalling events occurring upon binding of HDL to 
endothelial cells in more detail. 
Recently, Terasaka et al. [57] identified another mechanism whereby HDL may maintain 
endothelial cell NO availability in mice fed a high-cholesterol diet. These authors suggested 
that ABCG1-mediated efflux of oxysterols from endothelial cells may represent a novel 
effect whereby HDL promotes preservation of endothelial NO production (Fig. 2).   In 
particular,  7-ketosterol, a dietary oxysterol, accumulated in endothelial cells of ABCG1 
deficient mice on a western diet in vivo [57]. Interestingly, incubation of human aortic 
endothelial cells with HDL prevented 7-ketosterol-induced production of reactive oxygen 
species and disruption of the active eNOS dimer, suggesting that the ability of HDL to 
preserve endothelial function in the presence of hypercholesterolemia may at least in part 
relate to an increased endothelial efflux of 7-oxysterols [57]. 
 
2.3 HDL and anti-oxidant effects 
Accumulation and subsequent oxidation of LDL in the subendothelial space is thought to 
play an important role in the initiation and progression of atherosclerotic vascular disease, by 
leading to a pro-atherogenic form of LDL, i.e. oxidized LDL, that is taken up by scavenger 
receptors of macrophages [58].  In recent years, several studies have demonstrated that 
oxidatively modified LDL promotes endothelial cell inflammatory activation [59].  
Modification of LDL by 1-electron oxidants, such as tyrosyl radical or nitrogen dioxide 
radical, leads to the formation of lipid hydroperoxides and advanced products of oxidation, 
i.e. alkanes, aldehydes and isoprostanes [60-62].   Of note, HDL has been identified as a 
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major carrier of both early and late products of lipid oxidation [63, 64].  Moreover, it has 
been suggested that apoA-I, the main protein constituent of HDL, is capable of binding and 
removing lipid hydroperoxides of LDL in vitro, after injection into mice and after infusion in 
humans in vivo [61, 62]. HDL contains several anti-oxidant enzymes that may be involved in 
degradation of lipid hydroperoxides, such as paraoxonase-1 (PON-1), platelet-activating 
factor acetylhydrolase (PAF-AH), LCAT and reduced glutathione selenoperoxidase [65].  In 
particular, PON-1 has been suggested to be an important regulator of the anti-atherogenic 
capacity of HDL [66, 67]. Mice deficient in PON-1 displayed significantly larger aortic 
atherosclerotic lesions than their wild type controls and HDL isolated from mice deficient in 
PON-1 was unable to prevent oxidation of LDL in a cell co-culture model of the arterial wall 
[66].  
However, others have questioned the hypothesis that HDL directly acquires lipid 
hydroperoxides from LDL or is oxidized in plasma, because the transfer of lipid 
hydroperoxides between LDL and HDL appears to be slow and the plasma contains several 
anti-oxidant defense mechanisms [60]. Another explanation for the enrichment of lipid 
hydroperoxides in HDL could be the fact that HDL binds lipid oxidation products, such as 7-
ketocholesterol [57, 68], at sites of inflammation and transports them back to the plasma, 
thereby protecting endothelial cells against inflammatory activation [60]. Accordingly, 
Nicholls et al. [69] have reported that reconstituted HDL inhibits superoxide production and 
vascular inflammation induced by a non-occlusive carotid periarterial collar in 
normocholesterolemic rabbits.  In addition, Van Linthout et al. [70] have recently observed 
that human apoA-I gene transfer in rats with streptozotocin-induced diabetes mellitus resulted 
in a 1.9-fold increase in HDL cholesterol levels and reduced diabetes-induced angiotensin II 
type 1 receptor expression in the aorta of diabetic rats.  Concomitantly, the increased 
NAD(P)H oxidase activity observed in diabetic rats was inhibited by human apoA-I gene 
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transfer and this was at least in part due to a reduced mRNA expression of NOX4 and 
p22phox, two NAD(P)H oxidase subunits [70].  These data indicate that at least under 
hyperglycaemic conditions HDL may also exert anti-oxidative effects in the vascular wall by 
directly inhibiting angiotensin II type 1 receptor-mediated NAD(P)H oxidase activation and 
generation of reactive oxygen species. 
 
2.4 HDL and vascular and cardiac anti-inflammatory effects 
Atherosclerosis is considered as a chronic inflammatory disease. The endothelial adhesion 
and subsequent infiltration and  accumulation of monocytes/macrophages and T lymphocytes 
into the arterial intima represents a critical step in the initiation and progression of 
atherosclerotic lesions [58].  Notably, several studies have suggested that HDL can exert a 
variety of anti-inflammatory effects in endothelial cells, such as inhibition of the expression 
of monocyte chemoattractant protein (MCP)-1, an important pro-inflammatory chemokine 
that acts as an attractant for inflammatory cells adherent to endothelial cells [71, 72].  
Likewise, several studies have demonstrated that native HDL and reconstituted HDL 
containing apoA-I or the apoA-IMilano mutant inhibits the expression of leukocyte adhesion 
molecules in endothelial cells that are activated by pro-inflammatory stimuli [73-76].  In 
addition, native HDL has been suggested to inhibit endothelial monocyte adhesion induced 
by oxidized LDL [77] or TNF-α [76] and monocyte transmigration in co-cultures of HAEC 
and smooth muscle cells stimulated with LDL [71]. In vivo, infusions of reconstituted human 
HDL reduced VCAM-1 expression and decreased monocyte/macrophage infiltration 
following carotid artery cuff injury in apoE deficient mice [78].   Interestingly, in a recent 
study it was shown that apoA-I gene transfer did not only increase HDL cholesterol plasma 
levels, but also inhibited diabetes-induced myocardial mRNA expression of VCAM-1 and 
ICAM-1 in mice with streptozotocin-induced diabetic cardiomyopathy [79].  
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In contrast, in apoE deficient mice with transgenic overexpression of human apoA-I, 
endothelial VCAM-1 expression was not reduced in the aortic branch sites and was not 
associated with reduced monocyte adherence, despite reducing aortic atherosclerotic lesion 
formation [80].  Hence, the anti-inflammatory capacity of HDL may be heterogeneous. This 
is in line with findings of recent studies demonstrating that the inhibitory effects of HDL 
isolated from different human subjects on TNF-α stimulated endothelial VCAM-1 expression 
varied considerably [81, 82].  The reasons for the heterogeneous effects of HDL on 
endothelial cell inflammatory activation will have to be further defined.  Interestingly, more 
recently, it has been suggested that administration of reconstituted HDL (supplied by CSL 
Behring AG) increased the anti-inflammatory capacity of HDL from patients with type-2 
diabetes [83]. 
In this regard, in vitro studies using discoidal reconstituted HDL containing apoA-I as the 
sole protein suggested that the inhibitory effects of HDL on endothelial cell adhesion 
molecule expression are likely, at least in part, dependent on the HDL-associated 
phospholipid species [84]. The inhibition of cytokine-induced expression of VCAM-1 in 
human umbilical vein endothelial cells (HUVEC) by reconstituted HDL varied substantially 
when different phosphatidylcholine species were compared, supporting the concept that the 
composition of phospholipids in HDL may play a role for the anti-inflammatory capacity of 
HDL [12, 84]. 
Several mechanisms have been proposed to account for the inhibitory effect of HDL on 
endothelial inflammatory activation [12]. The ability of HDL to stimulate endothelial NO 
availability and to reduce superoxide production in endothelial cells may contribute to the 
anti-inflammatory effects of HDL, although direct evidence for this has not yet been 
published. Both, impaired endothelial NO bioavailability and increased endothelial 
superoxide production have been implicated in activation of the important pro-inflammatory 
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transcription factor NF-κB [85] and independent observations have demonstrated that HDL 
inhibits NF-κB activity [75, 76]. Interestingly, inhibition of TNF-α stimulated NF-κB activity 
by HDL was, at least in part, related to a decreased activity of endothelial sphingosine kinase 
[75]. Sphingosine kinase catalyzes the conversion of sphingosine to sphingosine-1-phosphate 
in endothelial cells, that represents an important step in the pathway by which TNF-α 
stimulates expression of adhesion molecules in the endothelium. 
 
2.5 HDL and inhibition of endothelial apoptosis and stimulation of endothelial repair 
Functional or structural disruption of endothelial integrity in response to major cardiovascular 
risk factors or by direct mechanical injury (i.e. after percutaneous coronary intervention), 
induces a variety of pro-inflammatory and proliferative responses in the arterial wall [86]. 
These responses likely contribute to initiation and progression of atherosclerotic plaque 
formation, vascular remodelling and development of restenosis [87]. Therefore, there is 
increasing interest in novel therapeutic approaches that maintain endothelial integrity by 
preventing endothelial cell apoptosis or promoting endothelial repair [86]. 
Of note, HDL has been shown to inhibit apoptosis of endothelial cells induced by several 
stimuli, such as TNF-α [88], oxidized LDL [89] and growth factor deprivation [90], i.e. HDL 
may likely inhibit death-receptor-mediated and mitochondrial-mediated apoptotic pathways 
(Fig. 3).  Depending on the pro-apoptotic stimulus, different compounds of HDL have been 
suggested to mediate the anti-apoptotic capacity of the lipoprotein. ApoA-I has been 
implicated in inhibition of endothelial cell apoptosis induced by oxidized LDL [89], VLDL 
[91] and  TNF-α [88]. Interestingly, a recent study suggested that HDL subpopulations 
enriched with apoA-I account for approximately 70% of the anti-apoptotic activity of HDL in 
human microvascular endothelial cells that were treated with mildly oxidized LDL and 
reconstitution of HDL with apoA-I, cholesterol and phospholipids potently decreased 
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oxidized LDL-induced apoptosis in these cells [92], suggesting that apoA-I indeed plays an 
important role for the anti-apoptotic capacity of HDL in oxidized LDL-stimulated endothelial 
cells.  
In contrast, HDL-associated lysosphingolipids have been shown to inhibit endothelial cell 
apoptosis induced by growth factor depletion [90, 93, 94]. The anti-apoptotic effects of 
sphingosylphosphorylcholine and lysosulfatide, two bioactive lysosphingolipids present in 
HDL particles, has been suggested to blunt activation of the mitochondrial-mediated pathway 
of apoptosis and may lead to activation of Akt that is known to be an important kinase for 
anti-apoptotic signalling in endothelial cells [90]. The role of HDL-associated 
lysosphingolipids for the anti-apoptotic effects of HDL was further suggested by another 
study demonstrating that the ratio of sphingosine-1-phosphate and sphingomyelin was 
increased in small dense HDL3 particles and positively correlated with the capacity of HDL 
subpopulations to attenuate endothelial cell apoptosis [95]. 
More recent work has also suggested that HDL may stimulate endothelial repair processes 
(Fig. 3).  Whereas endothelial repair process have long been thought of to be only dependent 
on the proliferation and migration of local adjacent endothelial cells [96], several recent 
studies have clearly suggested that bone-marrow-derived endothelial progenitor cells (EPC) 
may promote endothelial repair after vascular injury [97-99], contribute to endothelial repair 
processes in lesion-prone areas of experimental atherosclerosis [100] and improve endothelial 
function [101]. 
Recent work has suggested that HDL stimulates endothelial repair both, by promotion of 
endothelial cell proliferation or migration and stimulation of the recruitment and endothelial 
repair capacity of EPC [14, 102, 103].  HDL has consistently been shown to induce a marked 
increase in endothelial cell migration in vitro that is comparable to the effect of endothelial 
growth factors, such as basic fibroblast growth factor or vascular endothelial growth factor 
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[94, 102, 104].  Kimura et al. [94] demonstrated that native HDL and the HDL-associated 
lysosphingolipid sphingosine-1-phosphate stimulate migration of HUVEC and migration 
induced by HDL was potently inhibited either by antisense oligonucleotides against the 
sphingosine-1-phosphate receptors S1P1 and S1P3 or pertussis toxin (i.e. by inhibiting 
interactions between G proteins and G protein-coupled receptors). Moreover, the 
sphingosine-1-phosphate-rich fraction of HDL and sphingosine-1-phosphate purified from 
HDL stimulated endothelial cell migration, whereas the fraction containing other bioactive 
lysosphingolipids did not, suggesting that HDL-induced endothelial cell migration may be 
mediated by binding of sphingosine-1-phosphate to S1P1 and S1P3 [94]. The importance of 
sphingosine-1-phosphate for endothelial cell migration was supported by another study 
demonstrating that sphingosine-1-phosphate induced tube formation of human coronary 
artery endothelial cells in vitro by Ras/Raf1-dependent ERK activation [105]. 
In contrast, in a work by Seetharam et al. [102] pertussis toxin did not affect HDL-mediated 
endothelial cell migration, suggesting the presence of another pathway and agonist, which 
induces the migration of endothelial cells by HDL. Indeed, the authors observed that 
reconstituted HDL consisting of apoA-I, palmitoyloleylphosphatidylcholine and cholesterol 
was able to induce endothelial cell migration [102]. Moreover, native HDL induced rapid 
changes in the actin cytoskeleton of endothelial cells (i.e. a decrease in stress fibers, an 
increase in lamellipodia, and membrane ruffling) paralleled by an activation of the small 
GTPase Rac, that is known to mediate lamellipodia formation [102]. Interestingly, the 
authors were able to demonstrate that endothelial Rac activation and migration in response to 
HDL is independent of endothelial NO production, but requires binding of HDL to SR-BI 
and activation of Src kinase, PI3-kinase and MAP kinase [102]. Recently, the same group 
identified PDZ domain-containing protein PDZK1 as an adaptor protein of SR-BI in 
endothelial cells and suggested that PDZK1 is required for the initiation of HDL signalling 
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via SR-BI in endothelial cells and plays an important role for endothelial cell migration 
induced by HDL [103]. 
Interestingly, further studies have suggested that HDL and SR-BI promote re-
endothelialization of the carotid artery after perivascular electric injury in mice [14, 102].  In 
this model, carotid artery re-endothelialization was impaired in apoA-I deficient mice with 
low HDL levels as well as in SR-BI deficient mice [102]. Of note, reconstitution of apoA-I 
expression by liver-directed apoA-I gene transfer with subsequent normalisation of HDL 
plasma levels restored the re-endothelialization response in apoA-I deficient mice, strongly 
suggesting that apoA-I and HDL promote endothelial monolayer integrity in vivo [102].  In 
another study, elevation of HDL levels in apoE-deficient mice induced by adenoviral human 
apoA-I (AdA-I) transfer increased the number of Flk1 / Sca-1 double-positive cells in 
peripheral blood and the number of DiI-acLDL / FITC-isolectin double positive cells after 4 
days of ex vivo culture of spleen mononuclear cells [106]. Besides increasing the number of 
EPC, AdA-I transfer in apoE-deficient mice improved the migratory capacity of spleen-
derived early EPC in response to HDL, the adhesion of spleen-derived early EPC to 
fibronectin and the invasion of spleen-derived early EPC in solidified Matrigel [106]. Finally, 
AdA-I transfer also promoted the incorporation of EPCs in Balb/c common carotid artery 
allografts transplanted paratopically in C57BL/6 ApoE-/- mice that was associated with an 
increase in endothelial regeneration and inhibition of transplant arteriosclerosis [106].  In a 
follow-up study, the same group observed that murine and human early EPC express SR-BI, 
as indicated by immunocytochemistry analysis of human early EPCs and murine spleen-
derived early EPCs  after 4 and 7 days of ex vivo culture [107]. Of note, the authors did not 
observe an increase in circulating Flk1 / Sca-1 double-positive cells and DiI-acLDL / FITC-
isolectin double positive cells after ex vivo culture of spleen mononuclear cells after AdA-I 
transfer in mice transplanted with SR-BI deficient bone marrow, suggesting that expression 
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of SR-BI in bone marrow is critical for EPC mobilisation induced by HDL [107].  
Furthermore, the migratory capacity of bone-marrow derived early EPC deficient in SR-BI in 
response to HDL was reduced as compared to early EPC containing SR-BI and this was at 
least in part due to an impaired activation of extracellular signal-regulated kinases (ERK) and 
decreased NO production in SR-BI deficient early EPC [107]. In vivo, SR-BI deficiency in 
bone marrow abrogated the inhibitory effect of AdA-I transfer on allograft vasculopathy after 
paratopical transplantation of a common carotid artery of a female BALB/c donor mouse into 
the recipient male C57BL/6 mice, that was paralleled by impaired endothelial regeneration 
and EPC incorporation in allografts [107]. 
Besides increasing HDL levels by adenoviral human apoA-I transfer, intravenous infusion of 
reconstituted HDL has also been shown to increase the number of Sca-1 positive cells in the 
aortic endothelium of apoE deficient mice, supporting a role for HDL in promoting 
progenitor-mediated endothelial repair [108]. Furthermore, intravenous injection of 
reconstituted HDL increased blood flow recovery and capillary density in a murine ischemic 
hindlimb model [109]. 
 
3. HETEROGENEITY OF HDL PARTICLES 
Accumulating evidence suggests that the effects of HDL on cholesterol efflux from 
macrophages and on vascular cells, in particular endothelial cells, can be highly 
heterogeneous [110].  This may likely be secondary to changes in the HDL-associated 
proteom and lipids, i.e. changes in the amount and type of proteins and lipids bound as well 
as by protein and lipid modifications. In particular, oxidative modifications of HDL-
associated proteins, such as apoA-I, have been observed to impair the capacity of HDL to 
stimulate macrophage cholesterol efflux and to exert anti-inflammatory effect [111-114].  
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Moreover, HDL consists of a number of discrete subpopulations that vary in size, density, 
and composition of lipids and apolipoproteins [115]. Of note, the capacity of HDL particles 
of different size or structure to exert anti-atherogenic effects may differ [110]. For the anti-
inflammatory capacity of HDL it has been demonstrated that the smaller and denser HDL3 
subfraction was superior to the larger and less dense HDL2 subfraction in inhibiting TNFα-
induced VCAM-1 expression in endothelial cells [81]. To test whether the morphology and 
composition of HDL particles affects their anti-inflammatory capacity, discoidal and 
spherical reconstituted HDL particles of defined size and chemical composition have been 
studied for their ability to inhibit TNFα-induced VCAM-1 expression in endothelial cells 
[116].  In these studies, the anti-inflammatory capacity of HDL was not affected by variations 
in HDL particle size or in the composition of HDL-associated apolipoproteins, cholesteryl 
esters or triglycerides [116]. However, the anti-inflammatory capacity of HDL may be 
affected by the HDL-associated phospholipid content, as indicated by studies with 
reconstituted HDL containing apoA-I as the sole protein and different phosphatidylcholine 
species [84]. 
Importantly, in a seminal study by van Lenten et al. [82] it has been demonstrated that the 
anti-inflammatory capacity of HDL is affected by acute phase responses in both humans and 
rabbits.  The authors isolated human HDL from the same subjects before and after cardiac 
surgery and characterized the effects of HDL on LDL-induced monocyte transmigration and 
lipid hydroperoxide formation [82].  Before cardiac surgery, HDL completely inhibited the 
LDL-induced increase in monocyte transmigration and lipid hydroperoxide formation.  In 
marked contrast, “acute phase” HDL obtained from the same patients 2-3 days after surgery 
amplified the LDL-induced monocyte transmigration and was less effective in inhibiting lipid 
hydroperoxide formation, i.e. HDL in the same patient had been transformed from an anti-
inflammatory towards a pro-inflammatory particle [82]. Interestingly, the changes in HDL 
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functionality in this study were paralled by an increase in HDL-associated acute phase 
reactants (i.e. coeruloplasmin and serum amyloid A), while the activities of the HDL-
associated anti-oxidant enzymes paraoxonase and platelet-factor activating acetylhydrolase 
were reduced in acute phase HDL [82]. 
In subsequent years, we and others have observed that HDL loses important anti-
atherosclerotic and anti-inflammatory properties in patients with chronic inflammatory 
disorders, such as the antiphospholipid syndrome [13], systemic lupus erythematosus and 
rheumatoid arthritis [117], scleroderma [118], the metabolic syndrome [119], diabetes [14, 
120] and coronary disease [121]. Notably, in a study of 189 patients with chronic kidney 
disease on hemodialysis an impaired anti-inflammatory capacity of HDL was correlated with 
a poor clinical outcome, i.e. a reduced survival [122]. A further understanding of the 
mechanisms leading to altered vascular effects of HDL will be crucial also within the context 
of HDL-raising therapies, since it is likely, that only raising of HDL with vasoprotective 
properties will exert cardiovascular protection. 
 
4. POTENTIAL TREATMENT STRATEGIES TO RAISE HDL 
CHOLESTEROL PLASMA LEVELS AND/OR IMPROVE HDL 
FUNCTION 
 
The clinical potential and underlying mechanisms of HDL-targeted treatment strategies will 
be discussed in more detail in another review article within this issue of Curr Pharm Design 
[“High-density lipoprotein-raising strategies: update 2010”. Frank Spillmann, Sophie Van 
Linthout, Heinz-Peter Schultheiss, Carsten Tschöpe].  We will therefore largely limit the 
discussion here to the treatment-induced qualitative and functional changes of HDL. 
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4.1 Extended release niacin 
More than fifty years ago, Altschul and coworkers described for the first time the effect of 
supraphysiological doses of nicotinic acid, that is a water-soluble vitamin of the vitamin B 
complex, on total cholesterol plasma levels [123].   In particular the ability of nicotinic acid 
to substantially increase plasma concentration of HDL cholesterol has in recent years led to a 
substantial interest in the pharmacological potential of nicotinic acid for cardiovascular 
prevention [124].  In the Coronary Drug Project, treatment with nicotinic acid (3g/d) reduced 
the risk of definite nonfatal recurrent myocardial infarction in patients with a previous 
myocardial infarction in the follow-up after 8 years [125].  In the fifteen years follow-up 
study a lower all-cause mortality was observed in the group that was initially randomised to 
nicotinic acid therapy, however, the randomised treatment duration was limited to the first 8 
years [126]. Because of unfavourable side effects (i.e. cutaneous flushing and gastrointestinal 
side effects), the use of nicotinic acid in primary and secondary prevention of coronary 
disease has been limited, in particular in Europe, although nicotinic acid potently raises HDL 
cholesterol levels by up to 20 to 25% [127-129]. 
Interestingly, several recent studies have suggested that extended release (ER)-niacin therapy 
improves endothelial function in subjects without cardiovascular risk factors and low HDL 
levels and potentially in patients with coronary disease and low HDL levels [48, 130, 131].  
Notably, in a recent study, we have observed that ER-niacin therapy improved the capacity of 
HDL from patients with diabetes to stimulate endothelial NO production, to reduce 
endothelial superoxide levels and to promote early EPC-mediated endothelial repair 
processes [14]. Furthermore, the improvement of endothelial-protective properties of HDL, 
i.e. HDL functionality, from type-2 diabetic patients with metabolic syndrome and low HDL 
levels by ER-niacin treatment were accompanied by a reduction in the activity and content of 
HDL-associated myeloperoxidase, an enzyme that targets tyrosine and methionine residues of 
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apoA-I for oxidation [132], and a lowered lipid peroxidation state of HDL in these patients 
[14].  
Furthermore, in the HDL-Atherosclerosis Treatment Study (HATS), a combination therapy 
with nicotinic acid and simvastatin led to a reduction in the occurrence of a first 
cardiovascular event and in coronary atheroma volume in patients with coronary disease, low 
HDL and normal LDL cholesterol levels [133]. However, this study had a rather limited 
patient number to assess the effects of clinical outcome.  Moreover, there was no statin 
monotherapy group for comparison and the low dose of simvastatin (mean = 13 mg per day) 
was not in line with current recommendations. Notably, in the Arterial Biology for the 
Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2) study, ER-
niacin has been shown to reduce the progression of carotid intima media thickening over time 
in patients with coronary disease on statin therapy and low HDL levels after one year of 
follow-up, but the effect between the ER-niacin-treated group and the placebo group did not 
reach statistical significance [134]. However, the follow-on open label uncontrolled crossover 
study, ARBITER 3, reported a regression of carotid intima–media thickness after a further 12 
months of ER-niacin treatment [135]. In line with these findings, ER-niacin (2g daily) added 
to statin therapy significantly reduced carotid wall area as compared to placebo in a 
preliminary analysis of a double-blind randomized placebo-controlled study in patients with 
low HDL cholesterol (<40 mg/dl) and either type 2 diabetes with coronary heart disease or 
carotid/peripheral atherosclerosis [136].  More recently, the results of the ARBITER 6–
HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing 
Cholesterol 6–HDL and LDL Treatment Strategies) were presented addressing the question 
whether the addition of ezetimibe or the addition of ER-niacin is more effective in decreasing 
the progression of carotid intima–media thickness in patients with coronary heart disease or a 
coronary heart disease risk equivalent, who were receiving long-term statin therapy, and had 
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relatively low LDL and HDL cholesterol levels (<55 mg/dl for women or <50 mg/dl for men) 
[137]. In this study, the addition of extended-release niacin to statin therapy led to a decrease 
in the common carotid intima–media thickness, whereas no significant net changes in the 
carotid intima–media thickness were seen with the addition of ezetimibe [137].  In both, the 
HATS and the ARBITER studies the effect of ER-niacin therapy on HDL function has not 
been characterized. 
 
Currently, two large outcome trials, i.e. the National Heart, Lung, and Blood Institute (NIH) 
co-sponsored study AIM-HIGH and the HPS2-THRIVE, examine the effects of ER-niacin 
therapy on cardiovascular events in high-risk patients. The AIM-HIGH (Niacin Plus Statin to 
Prevent Vascular Events) trial randomizes more than 3000 patients with established vascular 
disease, atherogenic dyslipidemia including low HDL plasma levels (men <40 mg/dl, women 
< 50 mg/dl) to either simvastatin or an extended-release combination therapy of niacin and 
simvastatin.  The HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular 
Events) trial recruits 20,000 patients in the United Kingdom, China, and Scandinavia to 
determine if combining niacin with a new drug (MK-0524A) that minimizes flushing can 
reduce cardiovascular disease risk in patients that have already reached LDL cholesterol 
levels < 100 mg/dl.  
 
4.2 CETP inhibition 
The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from 
HDL to triglyceride-rich lipoproteins, which are subsequently cleared by hepatic LDL 
receptors [138]. By transferring cholesteryl esters from HDL toward apoB-containing 
lipoproteins in exchange for triglycerides, CETP decreases the concentration of HDL 
cholesterol and apoA-I, and increases the concentration of cholesteryl esters in VLDL and 
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remnants.  In addition, CETP activity raises levels of LDL cholesterol and apoB, at least in 
part due to a downregulation of hepatic LDL receptors, as described previously [139].  
Studies using neutralizing CETP monoclonal antibodies have demonstrated that CETP is 
responsible for all cholesteryl ester and triglyceride transfer activity in human plasma and 
inhibition of CETP leads to substantially increased HDL levels and a reduced cholesteryl 
ester content in VLDL [139]. 
Whereas studies in rabbits and humans have suggested that CETP does not stimulate the 
overall process of RCT [18, 140], a recent study in mice with CETP gene transfer suggested 
that CETP expression may promote macrophage RCT via the LDL-cholesterol receptor [43].  
Indeed, the lipoproteins mediating RCT may differ in the presence or absence of CETP 
activity, i.e. in the presence of CETP activity RCT may be mediated, at least in part, by 
remnants and LDL, and in the absence of CETP activity HDL-dependent RCT may be more 
important. Notably, the direct capacity of HDL to stimulate cholesterol efflux from 
macrophages (ABCG1-dependent) has been observed to be rather enhanced in CETP-
deficient subjects [44]. 
Of note, studies where the human CETP gene was introduced in atherosclerosis prone mice 
have yielded mixed results. In hypercholesterolemic apoE and LDL-receptor-deficient mice, 
and in a mouse model of mixed hyperlipidemia expressing apoE (Leiden), expression of 
CETP accelerated atherosclerosis [141-143]. However, in hypertriglyceridemic 
apolipoprotein CIII-transgenic mice expression of human CETP has been shown to be either 
non- or anti-atherogenic [144]. 
The relevance of CETP for HDL plasma levels in humans was identified first in Japanese 
families with inherited deficiency of CETP due to a gene splicing defect [145, 146]. Family 
members that were homozygous had moderate hypercholesterolemia, markedly increased 
levels of HDL cholesterol and apoA-I, and decreased levels of LDL cholesterol and apoB, as 
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compared to unaffected family members [146]. Members heterozygous for the deficiency had 
moderately increased levels of HDL cholesterol and apoA-I [146]. Despite these effects on 
the plasma lipoprotein profile, studies assessing the risk of coronary artery disease in subjects 
that are heterozygous for the CETP gene defect have yielded controversial results. In a cross-
sectional study of 3,469 men of Japanese ancestry in the Honolulu Heart Program, CETP 
gene mutations leading to decreased CETP activity and increased HDL cholesterol levels 
were associated with an increased risk for coronary heart disease [147]. In a seven-year 
follow-up study in 2,340 elderly men of the same population, aged 71 to 93 years, CETP 
mutations were associated with a lower incidence of coronary heart disease, however, the 
reduction in the incidence of coronary heart disease did not reach statistical significance 
[148].   A recent meta-analysis on individual patient data of 13,677 subjects from 7 large, 
population-based studies (each >500 individuals) and 3 randomized placebo-controlled 
pravastatin trials suggested that the CETP TaqIB variant is associated with HDL-cholesterol 
plasma levels and more importantly with coronary disease risk [149].  Furthermore, a recent 
study characterizing the association of CETP genotypes leading to a moderate reduction in 
CETP activity and coronary risk pointed towards a weakly inverse association with coronary 
risk [8]. 
The finding of elevated HDL cholesterol levels in Japanese families with genetic CETP 
deficiency, spurred the interest in pharmacological inhibition of CETP as a novel therapeutic 
approach to raise HDL cholesterol levels. However, torcetrapib, the first CETP inhibitor that 
was characterized in large clinical trials, failed to reduce progression of carotid 
atherosclerosis in patients with familial hypercholesterolemia that were on statin treatment, 
and was associated with progression of disease in the common carotid segment [150]. Of 
note, these effects occurred despite a pronounced increase in HDL cholesterol levels and a 
substantial decrease in LDL cholesterol and triglycerides levels [150]. More importantly, in 
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the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic 
Events (ILLUMINATE) study, a large clinical outcome trial characterizing the effects of 
torcetrapib on major cardiovascular events in patients at high cardiovascular risk who were 
receiving statins, torcetrapib therapy was associated with an increased morbidity and 
mortality [151]. The exact reasons for the adverse outcome are still not entirely clear. 
However, in the patient population that was studied in ILLUMINATE, torcetrapib therapy 
was associated with a number of potential off-target effects, such as increases in blood 
pressure, sodium, bicarbonate and aldosterone levels, and a decrease in potassium levels, that 
could account, at least in part, for the increase in adverse cardiovascular events. 
Importantly, two different CETP inhibitors, the smaller molecules dalcetrapib and 
anacetrapib,  do not seem to increase blood pressure are currently evaluated in clinical trial 
programs [152]. Anacetrapib (MK-0859, Merck) has been shown to effectively raise HDL 
cholesterol levels in patients with dyslipidemia after 4 weeks of therapy without affecting 
blood pressure levels in a 24-h ambulatory blood pressure study [153]. Comparable effects 
were seen in 589 patients with hypercholesterolemia or mixed hyperlipidemia and in this 
study 8 weeks of anacetrapib treatment led to an increase in HDL cholesterol by up to 139% 
[154]. Of note, co-administration of anacetrapib with atorvastatin resulted in significant 
incremental LDL cholesterol reductions and similar HDL cholesterol increases, as compared 
to atorvastatin therapy alone [154]. An ongoing phase III trial is characterizing the effects of 
anacetrapib treatment on the plasma lipoprotein profile and safety in patients with coronary 
disease or a coronary disease risk-equivalent. 
The CETP-inhibitor dalcetrapib (Roche) has been shown to confer a more modest inhibition 
of CETP activity and is currently evaluated in a large clinical trial program (dalcetrapib HDL 
evaluation, atherosclerosis and reverse cholesterol transport [dal-HEART] program), that will 
assess the effects of dalcetrapib on endothelial function (dal-Vessel study), atherosclerotic 
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disease progression (dal-PLAQUE) and cardiovascular outcome in stable patients with a 
recent acute coronary syndrome (dal-OUTCOME morbidity and mortality study). 
Interestingly, studies from the group of Alan Tall have recently suggested that in CETP-
deficient subjects as compared to normolipidemic controls and in healthy, moderately 
hyperlipidemic subjects after treatment with the CETP inhibitor torcetrapib the capacity of 
HDL to promote macrophage cholesterol efflux was rather increased [44, 155].  Similarly, 
Catalono et al. [156] have observed, that torcetrapib rather enhanced the subnormal capacity 
of HDL2 particles from dyslipidemic patients to mediate free cholesterol efflux via both SR-
BI and ABCG1 pathways in hyperlipidemic subjects.  However, the effect of CETP 
inhibition on the direct vasoprotective properties of HDL remains to be characterized.  
 
4.3 Reconstituted HDL, apoA-I mimetics and apoA-I inducer 
Experimental studies in mice using transgenic or somatic gene transfer approaches have 
suggested that overexpression of the human apoA-I gene leads to increases in apoA-I and 
HDL cholesterol [157-159], and may thereby reduce progression of atherosclerosis [157, 
158]. Moreover, apoA-I overexpression in mice has been shown to promote RCT from 
macrophages to feces in mice [160]. Therefore, therapeutic strategies that aim to raise plasma 
concentrations of apoA-I and hence HDL levels are currently intensely studied and include 
the infusion of lipid-free apoA-I, reconstituted HDL (i.e. CSL-111) or mutant apoA-I [152]. 
More recently, a compound (RVX-208, Resverlogix) has entered first clinical safety and 
pharmacokinetic studies, that enhances apoA-I expression in the liver. 
Of note, an intravenous infusion of lipid-free apoA-I in men with low HDL cholesterol (<40 
mg/dl) has been shown to increase total apoA-I and HDL phospholipid concentration in 
plasma, without affecting the levels of unesterified or esterified cholesterol in HDL [161]. 
Moreover, intravenous infusion of apoA-I/phosphatidylcholine disks (reconstituted HDL) has 
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been demonstrated to increase plasma apoA-I concentration (in particular in small prebeta-
migrating particles) and unesterified cholesterol in total HDL [162]. After stopping the 
infusion, the authors observed an increase in cholesteryl ester content of HDL and large 
alpha-migrating apoA-I containing HDL, suggesting that the infusion of apoA-
I/phosphatidylcholine disks may increase the intravascular production of small pre-beta HDL 
in vivo, and that this may be associated with an increase in the efflux and esterification of 
unsterified cholesterol [162]. Likewise, in patients with familial hypercholesterolemia the 
intravenous infusion of human pro-apoA-I (a precursor of apoA-I) liposome complexes led to 
an increase in plasma levels of apoA-I and HDL, and was associated with an increase in fecal 
cholesterol excretion (i.e. neutral sterols and bile acids) over a period of 9 days after injection 
[163]. 
A small double-blind, randomized, placebo-controlled pilot study by Nissen et al. [164] 
examined the effects of 5 intravenous injections of recombinant apoA-I Milano / phospholipid 
complexes (ETC-216) on coronary atheroma burden in patients with an acute coronary 
syndrome. ApoA-I Milano is a rare point mutation in apoA-I that has been identified in a small 
number of individuals in northern Italy and subjects carrying the apoA-I Milano mutation 
display low HDL cholesterol and apoA-I levels, but no clear increase in the risk of 
cardiovascular disease, that has lead to the suggestion that this may be a particularly 
vasoprotective variant of apoA-I [165]. Intravenous infusions of recombinant apoA-IMilano/ 
phospholipid complexes (five doses at weekly intervals) resulted in a small, but significant 
regression of coronary atheroma volume, as detected by IVUS, compared with no significant 
change from baseline in the placebo group [164]. 
Moreover, recently a randomized placebo-controlled trial examined the effects of intravenous 
infusion of reconstituted HDL on coronary plaque burden as assessed by intravascular 
ultrasound (IVUS), and included 145 patients that had evaluable serial IVUS examinations 
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[166]. Patients were randomly assigned to receive 4 weekly infusions of reconstituted HDL 
(CSL-111, consisting of apoA-I isolated from human plasma and phosphatidylcholine 
derived from soybean in a molar ratio of 1:150) or placebo [166]. After six weeks of follow-
up, the short-term infusion of reconstituted HDL did not result in a significant reduction in 
percentage change in atheroma volume or nominal change in plaque volume compared with 
placebo. However, the authors observed a statistically significant improvement in the plaque 
characterization index [166]. 
Interestingly, a study from our department was able to demonstrate that intravenous infusion 
of reconstituted HDL rapidly restored the impaired endothelium-dependent vasodilation in 
hypercholesterolemic patients, as detected by forearm venous occlusion plethysmography, 
suggesting a potential therapeutic benefit of this approach in patients at risk for 
atherosclerosis [53].  Moreover, in 9 subjects with low HDL that were ABCA1 
heterozygotes, impaired endothelium-dependent vasodilation was restored by apoA-
I/phosphatidylcholine (apoA-I/PC) disks administration [52]. 
Another approach for raising apoA-I plasma level is that of using apoA-I mimetics, i.e. 
peptides structurally and functionally related to apoA-I. Numerous studies have suggested 
that apoA-I mimetics possess atheroprotective effects in animal models, and these 
compounds are now entering first clinical trials [167, 168].  
 
5. CONCLUSION 
Low HDL plasma concentrations are associated with a substantially increased coronary heart 
disease risk. Over the past years numerous studies have shed light on the mechanisms 
whereby HDL may exert anti-atherosclerotic effects. In particular, promotion of cholesterol-
efflux from lipid loaded macrophages via ABCA1 and ABCG1, anti-inflammatory, anti-
thrombotic and endothelial-protective effects of HDL have been identified. At the same time 
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it has become clear, that the vascular-protective properties of HDL are heterogeneous and 
may be impaired in patients at high cardiovascular risk. Therefore, HDL-targeted strategies 
should likely not only increase HDL plasma levels, but also lead to an on-treatment HDL 
with potent anti-atherosclerotic properties. Finally, successful HDL-targeted therapies may 
promote regression of atherosclerosis.  
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Figure Legends 
Fig. (1). Potential athero-protective effects of HDL. Besides promoting cholesterol efflux 
and reverse cholesterol transport from macrophages in the atherosclerotic lesion back to the 
liver for excretion in the bile, HDL has been suggested to exert important direct endothelial-
protective effects. In particular, HDL has been shown to stimulate endothelial nitric oxide 
(NO) production and endothelium-dependent, NO-mediated vasodilation, to exert anti-
oxidant, anti-inflammatory and anti-thrombotic effects in endothelial cells, and to promote 
endothelial repair processes. 
 
Fig. (2). Endothelial NO synthase (eNOS) activating signaling pathways in endothelial 
cells stimulated by HDL.  HDL has been shown to stimulate eNOS phosphorylation at 
serine residue 1177 via binding of the major apolipoprotein in HDL, apoA-I, to SR-BI and 
via binding of HDL-associated lysosphingolipids (SPC, S1P, LSF) to the S1P3 receptor. In 
addition it has been suggested that HDL increases eNOS protein abundance in endothelial 
cells by increasing the half-life of eNOS, likely at least in part via Akt/MAP kinase signaling. 
Moreover, a recent study has suggested that HDL increases eNOS activity in mice on a high-
cholesterol diet by promoting endothelial efflux of 7-ketosterol (7-KC) via ABCG-1 and by 
preserving active eNOS dimer levels. 
 
Fig. (3). Effect of HDL on endothelial cell apoptosis and endothelial repair. Recent 
studies have suggested that apoA-I may protect endothelial cells against apoptosis induced by 
TNFα, oxLDL and VLDL. In contrast, HDL-associated lysosphingolipids may confer 
protection against endothelial cell apoptosis induced by growth factor deprivation. 
Furthermore, HDL has been demonstrated to stimulate endothelial cell migration either by 
binding of apoA-I to SR-BI or by binding of sphingosine-1-phosphate to its receptors, S1P1 
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and S1P3. In addition, recent studies have suggested that HDL improves endothelial repair 
process, in part by stimulating EPC-mediated endothelial repair capacity.   
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